RecruitingNCT07270861

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

A Multicenter, Non-interventional, Two-cohort Study to Describe Real-world Treatment Patterns and Outcomes in Patients With Peripheral T-cell Lymphoma


Sponsor

Fudan University

Enrollment

3,000 participants

Start Date

Nov 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
  • Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
  • Cohort B: Patients newly diagnosed from October 2025 onward.
  • Availability of basic diagnostic and treatment records .

Exclusion Criteria3

  • Indeterminate diagnosis or missing pathology report.
  • Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
  • Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.

Interventions

OTHERObservational

Observational


Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07270861


Related Trials